# Arsenic Trioxide in Treating Patients With Urothelial Cancer

> **NCT00009867** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
- Recurrent Urethral Cancer
- Transitional Cell Carcinoma of the Bladder
- Ureter Cancer

## Interventions

- **DRUG:** arsenic trioxide

## Key facts

- **NCT ID:** NCT00009867
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** 2004-06
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00009867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00009867, "Arsenic Trioxide in Treating Patients With Urothelial Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00009867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*